- TRADE NAME: Mulpleta (Shionogi)
- INDICATIONS: indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
- CLASS: Thrombopoietin receptor (TPO) agonist
- HALF-LIFE: ~27 hours
- FDA APPROVAL DATE: 07/31/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: no available data to inform the drug-associated risk
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 02/16/2024
